» Articles » PMID: 29409351

CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype

Overview
Journal Hum Gene Ther
Specialties Genetics
Pharmacology
Date 2018 Feb 8
PMID 29409351
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Acute myeloid leukemia (AML) is a kind of a malignant hematologic tumor caused by uncontrolled repopulation of myeloid hematopoietic stem cells (HSCs). Current therapeutic effects for AML patients are unsatisfactory. In particular, relapsed and refractory AML still have a poor prognosis. T cells modified by chimeric antigen receptor (CAR) was an immunotherapeutic strategy for malignancies, which has a broad developing prospect. Most AML cells overexpress the myeloid antigen CD33. Therefore, CD33-specific CAR-T cells with different co-stimulators (CD28, 4-1BB, or both, referred to as CD33 28z.CAR-T cells, CD33 BBz.CAR-T cells, or CD33 28BBz.CAR-T cells, respectively) were developed to evaluate their efficacy against AML. The effectiveness of three types of CD33 CAR-T cells against AML was verified by specific killing effect to AML cells and prolonged survival of a xenograft mouse model. In terms of CAR-T cell efficacy, especially when transfused into human bodies, the persistence of T cells is also an important index, as it is closely associated with the long-term effect of CAR-T cells. Therefore, the characteristics of three types of CD33 CAR-T cells related to the persistence of T cells were examined. It was found that during expansion, CD33 BBz.CAR-T cells had an increased central memory compartment, while CD33 28z.CAR-T cells were predominantly effector memory T cells. In addition, CD33 28z.CAR-T cells were more inclined to become exhausted. The study suggests that incorporation of 4-1BB in CARs may endow T cells with long-lasting survival ability, thus improving the long-term anti-leukemia effect of CAR-T cells, especially when transfused to the human body.

Citing Articles

CAR-T Therapy Beyond B-Cell Hematological Malignancies.

Canichella M, de Fabritiis P Cells. 2025; 14(1.

PMID: 39791742 PMC: 11719893. DOI: 10.3390/cells14010041.


Loop33 × 123 CAR-T targeting CD33 and CD123 against immune escape in acute myeloid leukemia.

Ma H, Yan Z, Gu R, Xu Y, Qiu S, Xing H Cancer Immunol Immunother. 2024; 74(1):20.

PMID: 39535595 PMC: 11561222. DOI: 10.1007/s00262-024-03847-7.


Specific ECM degradation potentiates the antitumor activity of CAR-T cells in solid tumors.

Zheng R, Shen K, Liang S, Lyu Y, Zhang S, Dong H Cell Mol Immunol. 2024; 21(12):1491-1504.

PMID: 39472748 PMC: 11606952. DOI: 10.1038/s41423-024-01228-9.


Identifying ADGRG1 as a specific marker for tumor-reactive T cells in acute myeloid leukemia.

Mei Y, Liu Y, Liu W, Chen M, Liu X, Wang S Exp Hematol Oncol. 2024; 13(1):92.

PMID: 39243082 PMC: 11380426. DOI: 10.1186/s40164-024-00560-0.


Cell-Based Treatment in Acute Myeloid Leukemia Relapsed after Allogeneic Stem Cell Transplantation.

Canichella M, de Fabritiis P Biomedicines. 2024; 12(8).

PMID: 39200186 PMC: 11351713. DOI: 10.3390/biomedicines12081721.